JX1.1-pyrrolobenzodiazepine

**JX1.1-pyrrolobenzodiazepine** is a preclinical, TRBC2-directed antibody-drug conjugate developed at Johns Hopkins University for TRBC2-positive T-cell malignancies, including T-cell lymphomas and leukemias. Its JX1.1 antibody component selectively recognizes T-cell receptor beta constant 2, enabling preferential delivery of a pyrrolobenzodiazepine dimer cytotoxic payload to TRBC2-expressing malignant T cells while sparing the TRBC1-positive normal T-cell compartment. Following target binding and cellular internalization, the pyrrolobenzodiazepine payload damages DNA, producing potent cytotoxicity. The ADC demonstrated selective in-vitro activity and durable tumor regression in mouse models, but no human clinical development has been reported. ([pure.johnshopkins.edu](https://pure.johnshopkins.edu/en/publications/trbc2-targeting-antibodydrug-conjugates-for-the-treatment-of-t-ce/))

Other names

JX1.1-SG3249JX-1.1-SG3249JX 1.1-SG3249